Protein-based vaccine uses purified pieces of the virus to spur an immune response, a technology that has been used to combat hepatitis B and influenza.
Will continue to support communities in need with no-cost COVID-19 testing through the end of the year via the federal Operation Expanded Testing program.
Analysis of VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus).
Includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain.
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021.
Made possible through Premier tracking technologies, cold chain solutions, and expansive, sophisticated, global network providing UPS Healthcare services.
New manufacturing lines to provide U.S. govt. with access to hundreds of millions of needles and syringes to support U.S. vaccination agility and preparedness.
462,000 square foot state-of-the-art building targeting LEED Zero certification and designed to be the most sustainable commercial lab building in Cambridge, MA